Stefan Oschmann to Hand Over Chair of Executive Board to Belén Garijo in 2021
- Stefan Oschmann’s successful tenure to be completed as planned by end of April 2021
- Belén Garijo nominated as Chair of Executive Board and CEO effective May 1, 2021; ensuring seamless transition and continuity in corporate management
- Two internationally experienced managers to join Executive Board
- Peter Guenter will take over responsibility for Healthcare business sector
- Matthias Heinzel will be in charge of Life Science business sector
Stefan Oschmann will hand over the Chair of the Executive Board of Merck KGaA, Darmstadt, Germany, to Belén Garijo in 2021. The Board of Partners of E. Merck KG, Darmstadt, Germany, has appointed Garijo as new Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany, effective May 1, 2021. She is currently Vice Chair of the Executive Board and Deputy CEO of Merck, KGaA, Darmstadt, Germany, as well as CEO Healthcare. Oschmann will leave the company as planned after ten years on the Executive Board, five of them as Chairman and CEO, to turn to other tasks.
“I would like to thank Stefan Oschmann for an extremely successful tenure on the Executive Board of Merck KGaA, Darmstadt, Germany. He has significantly shaped the company’s transformation into a globally leading science and technology company. Everyone who thinks of Merck KGaA, Darmstadt, Germany, today, immediately thinks of science & tech – and this worldwide. The company’s extremely strong portfolio, its excellent company valuation and its bright future prospects are closely connected with Stefan Oschmann. He has especially driven the company’s turn to digital innovations and business models forward. Merck KGaA, Darmstadt, Germany, will substantially benefit from this in the long run,” said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG, Darmstadt, Germany.
“With Belén Garijo an internationally very experienced and highly recognized manager will take over the Chair of the Executive Board of Merck KGaA, Darmstadt, Germany. She knows our company extremely well and has done excellent work in transforming our Healthcare business sector. Belén Garijo and Stefan Oschmann have been collaborating closely and trustfully for many years. This will ensure a seamless transition and continuity in corporate management,” said Johannes Baillou.
Peter Guenter will join the Executive Board of Merck KGaA, Darmstadt, Germany, effective January 1, 2021, at the latest. He will assume board responsibility for the Healthcare business sector and will be located in Darmstadt, Germany. Since 2017, Guenter has been CEO of the publicly listed pharma company Almirall in Barcelona, Spain. Like Merck KGaA, Darmstadt, Germany, the company is predominantly family owned. The Belgian national previously held various country, regional and global management positions at Sanofi since 1995, last as Executive Vice President Global Diabetes and Cardiovascular. Guenter holds a Master’s degree in Physical Education from the Faculty of Medicine and Health Sciences of the University of Ghent, Belgium.
“Peter Guenter has many years of experience and profound knowledge of the international pharma sector. Together with our global team he will work on ensuring a successful future of our Healthcare business. Merck KGaA, Darmstadt, Germany, has an attractive pipeline and is well positioned in key markets. That is the perfect basis for future growth,” said Johannes Baillou.
Matthias Heinzel will join the Executive Board of Merck KGaA, Darmstadt, Germany, effective April 1, 2021, at the latest. He will assume board responsibility for the Life Science business sector and will be located in Burlington, Massachusetts, and Darmstadt, Germany. Heinzel is currently President Nutrition & Biosciences at DuPont and is based in Copenhagen, Denmark. He is a Member of DuPont’s Executive Board. Prior to that he held various global executive positions at DuPont in the U.S. and Germany since 2003. The German national studied industrial engineering at the Technical University Darmstadt, Germany, and holds a doctorate in business administration. He started his career at McKinsey.
“The Covid-19 pandemic has once again emphasized the potential of our Life Science business sector as a problem solver. We are happy that Matthias Heinzel, who is an internationally experienced manager, will join us to take over this important position in a strongly innovation-driven environment. Together with our global Life Science team he will further strengthen our successful activities,” said Johannes Baillou.
Kai Beckmann and Marcus Kuhnert will continue to pursue their current tasks as Members of the Executive Board. As of May 2021, the Executive Board of Merck KGaA, Darmstadt, Germany, will be structured as follows:
Belén Garijo, Chair of the Executive Board and CEO
Board responsibility for Group functions Communications / Corporate Affairs / Environment, Health, Safety, Security, Quality / Human Resources / Internal Auditing / Legal & Compliance / Strategy & Transformation
Kai Beckmann, Member of the Executive Board
CEO Performance Materials and Board responsibility for Group functions Inhouse Consulting / Patents & Scientific Information / Site Operations
Peter Guenter, Member of the Executive Board
Matthias Heinzel, Member of the Executive Board
CEO Life Science
Marcus Kuhnert, Member of the Executive Board
Chief Financial Officer and Board responsibility for Group functions Information Technology / Procurement / Merck KGaA, Darmstadt, Germany, Business Services
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
MilliporeSigma today announced a collaboration with Mammoth Biosciences Inc. for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test.